Nusinersen
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Muscular Atrophy, Spinal
Conditions
Muscular Atrophy, Spinal
Trial Timeline
Jan 4, 2021 → Oct 9, 2025
NCT ID
NCT04488133About Nusinersen
Nusinersen is a approved stage product being developed by Biogen for Muscular Atrophy, Spinal. The current trial status is completed. This product is registered under clinical trial identifier NCT04488133. Target conditions include Muscular Atrophy, Spinal.
What happened to similar drugs?
14 of 20 similar drugs in Muscular Atrophy, Spinal were approved
Approved (14) Terminated (2) Active (5)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02865109 | Pre-clinical | Completed |
| NCT06555419 | Phase 1 | Recruiting |
| NCT05067790 | Phase 3 | Active |
| NCT04729907 | Phase 3 | Active |
| NCT04488133 | Approved | Completed |
| NCT04089566 | Phase 3 | Completed |
| NCT04591678 | Pre-clinical | Completed |
| NCT02594124 | Phase 3 | Completed |
| NCT02462759 | Phase 2 | Terminated |
| NCT02386553 | Phase 2 | Completed |
| NCT02292537 | Phase 3 | Completed |
| NCT02193074 | Phase 3 | Terminated |
| NCT02052791 | Phase 1 | Completed |
| NCT01839656 | Phase 2 | Completed |
| NCT01780246 | Phase 1 | Completed |
| NCT01703988 | Phase 1/2 | Completed |
| NCT01494701 | Phase 1 | Completed |
Competing Products
20 competing products in Muscular Atrophy, Spinal